| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive's clonoSEQ® test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.
Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status.
This integration will be effective as of today, July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.
Posted In: ADPT
